Day one at the Association of Early Pregnancy Units (AEPU) Annual Scientific Meeting in Liverpool!

AEPU brings together the UK’s early pregnancy community: the senior clinicians, nurses, midwives and sonographers who care for women through some of the most anxious weeks of their lives, alongside the researchers and industry working to improve that care. The meeting is sold out, and yesterday’s science set a very high bar.

A highlight for us was Professor Siobhan Quenby MBE, Chief Investigator of our FREEDOM trial, updating delegates on the study. She spoke openly about something every clinician in the room recognised: the anxiety women feel about leaky pessaries, at what is already an uncertain time in their pregnancy 🙏

She also described the journey. Before the first participant was dosed, 400mg progesterone Callavid® went through extensive testing, from dissolution to syngina testing, followed by research ethics approval and MHRA authorisation to begin a first-in-human trial. These things take time, as they should.

Today, FREEDOM, our NIHR-funded first-in-human trial of 400mg progesterone Callavid® for threatened miscarriage and luteal phase support in IVF, is fully recruited and will complete shortly.

We’re proud to be joined by research midwives from University Hospitals Coventry and Warwickshire (UHCW) NHS Trust, the people who made that recruitment happen, alongside our Project Manager, Kaylie Mings. The stand was busy all day 💥 and the enthusiasm for #Callavid from the people who treat these women every day means a great deal to us.

Thank you to the AEPU team, and to NIHR (National Institute for Health and Care Research) for making FREEDOM possible.